Dr. Dino PratoEnvita Medical Centers · Founder and CEO at Envita Medical Centers

Blood cancer recurrence doesn’t always mean treatment failed #shorts

4 Mar 2026 · 1 min

Watch on YouTube

0:32

In this short monologue, the speaker likens minimal residual disease (MRD) in blood cancers to lingering embers after a wildfire—tiny, dormant cancer cells that can reignite disease when conditions allow. The speaker emphasizes that eliminating MRD requires a precise, targeted immune-based approach, a form of precision oncology that delivers a short, controlled strike against these remnants, especially effective when the overall disease burden is low. The central message is that while MRD is resistant and hidden, a focused immune attack can eradicate it and prevent relapse.

Chapters

Minimal residual disease is the last crumb of the cancer. It's like embers after a wildfire. They resist treatment. They hide. They go in these quiet places, and they become dormant. And one gust of wind can bring the fire back. And so the mission becomes simple. Can we get rid of it? And there's a way to do that. You usually need immune power, but in this case, it's a unique targeted power. With precision oncology for blood cancers, A short, controlled, targeted immune strike makes all the difference, Especially when the disease burden is low. And when we're talking about minimal residual disease,